Fulfilling the vision treatment of many incurable diseases by the use of continuously proliferating and differentiating into all tissues of the body of human embryonic stem cells ( HP) has so far not gone beyond the experimental stage preclinical studies . Numerous attempts to apply for the same purposes somatic HP derived from mature tissue yielded only moderate clinical effects . The article presents the basic difficulties which slow down the development of cell therapy .